These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30538097)

  • 1. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.
    Cross AJ; Wooldrage K; Robbins EC; Kralj-Hans I; MacRae E; Piggott C; Stenson I; Prendergast A; Patel B; Pack K; Howe R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran SP; Atkin WS
    Gut; 2019 Sep; 68(9):1642-1652. PubMed ID: 30538097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
    Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
    Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
    Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using a hypothetical scenario to assess public preferences for colorectal surveillance following screening-detected, intermediate-risk adenomas: annual home-based stool test vs. triennial colonoscopy.
    Bonello B; Ghanouni A; Bowyer HL; MacRae E; Atkin W; Halloran SP; Wardle J; von Wagner C
    BMC Gastroenterol; 2016 Sep; 16(1):113. PubMed ID: 27618798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative cost-effectiveness of colorectal cancer screening using faecal immunochemical test vs. colonoscopy.
    Wong MC; Ching JY; Chan VC; Sung JJ
    Sci Rep; 2015 Sep; 5():13568. PubMed ID: 26338314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
    Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
    United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study.
    Cross AJ; Robbins EC; Pack K; Stenson I; Kirby PL; Patel B; Rutter MD; Veitch AM; Saunders BP; Little M; Gray A; Duffy SW; Wooldrage K
    Health Technol Assess; 2022 May; 26(26):1-156. PubMed ID: 35635015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Colorectal Cancer Risk After Resection of High-Risk Pedunculated Polyps.
    Zorzi M; Battagello J; Amidei CB; Antonelli G; Germanà B; Valiante F; Benvenuti S; Tringali A; Bortoluzzi F; Cervellin E; Giacomin D; Meggiato T; Rizzotto ER; Fregonese D; Dinca M; Baldassarre G; Scalon P; Pantalena M; Milan L; Bulighin G; Di Piramo D; Azzurro M; Gabbrielli A; Repici A; Rugge M; ; Hassan C
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1518-1527.e7. PubMed ID: 38325601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy, Acceptability, and Application: Fecal Immunochemical Tests for Early Detection of Advanced Neoplasia in Colonoscopy-Based Surveillance.
    Wassie MM; Dix M; Laven-Law G; Bulamu N; Cock C; Bampton P; Fraser RJ; Winter JM; Young GP; Symonds EL
    Dig Dis Sci; 2024 Jul; 69(7):2621-2630. PubMed ID: 38753241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colonoscopy findings after increasing two-stool faecal immunochemical test (FIT) cut-off: Cross-sectional analysis of the SCREESCO randomized trial.
    Westerberg M; Eriksson J; Metcalfe C; Löwbeer C; Ekbom A; Steele R; Holmberg L; Forsberg A
    J Intern Med; 2024 Aug; 296(2):187-199. PubMed ID: 38845164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
    Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
    Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis.
    Meester RGS; Lansdorp-Vogelaar I; Winawer SJ; Zauber AG; Knudsen AB; Ladabaum U
    Ann Intern Med; 2019 Nov; 171(9):612-622. PubMed ID: 31546257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
    de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
    Kelley L; Swan N; Hughes DJ
    Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China.
    Wang L; Chen H; Zhu Y; Lu M; Wang Y; Chen X; Ma W; Du L; Chen W
    BMJ Open; 2022 May; 12(5):e059754. PubMed ID: 35589365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.